Skip to main content

Crescent Biopharma, Inc.

corporate_fare Company Profile

Crescent Biopharma, Inc.

CBIO·NASDAQ·Life Sciences·CIK 0001253689

GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on developing therapies for people with cancer. The company was incorporated in Delaware in 2003 and, on June 16, 2025, changed its jurisdiction of incorporation to the Cayman Islands. It operates through two distinct strategies to build its portfolio. First, it is developing CR-001, a PD-1 x VEGF bispecific antibody designed to bind both the PD-1 immune checkpoint and Vascular Endothelial Growth Factor. This product has the potential to replace pembrolizumab, marketed as Keytruda®, as a foundational immuno-oncology treatment. A global Phase 1/2 trial of CR-001, known as the ASCEND trial, was initiated in February 2026. Second, the company is building a portfolio of antibody drug conjugates (ADCs). The company intends to combine CR-001 and ADC therapies. It anticipates initiating CR-002 and CR-003 monotherapy clinical trials in 2026, as well as the first ADC combination trial with CR-001 in the same year.

Crescent Biopharma, Inc. (NASDAQ:CBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for CBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CBIO spans 10-Q, 8-K, SCHEDULE 13D/A, 424B5.

Recent high-impact activity:

  • Crescent Biopharma Posts $289.4M Cash, Runway Into H2 2028 as Q3 Loss Widens
  • Crescent Biopharma Q3: $289.4M Cash, $37.7M Quarterly Loss, CR-002 Trial Underway
  • Crescent Biopharma Lays Out CR-001/CR-002/CR-003 Data Calendar; APOLLO Starts Q4 2026
  • FDA Clears IND for Crescent's PD-L1 ADC CR-002, Phase 1/2 APOLLO Trial to Start Q4
  • Crescent Biopharma Q2 Loss Narrows to $24.8M; Pro Forma Cash Hits $305M, Runway Into 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$10.84M
Net Income
-$153.94M
Op. Cash Flow
-$71.53M
Free Cash Flow
-$72.45M
Operating Income
-$152.63M
Cash & Equivalents
$213.19M
Debt / Equity
0.00×
Net Margin
-14.20×
Shares Outstanding
27.56M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-011983

Short Interest & Short Volume

16.29 days to cover

FINRA reported short interest of 4,160,829 shares in CBIO as of the October 30, 2026 settlement, a 5.8% decrease from the prior period — about 16.3 days to cover at its recent average daily volume. On November 20, 2026, 59.9% of CBIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,160,829 shares as of October 30, 2026
Change vs prior period▼ 5.8%
Days to cover16.29 at avg daily volume of 255,474
Daily short volume (FINRA facilities)59.9% of 166,348 shares on November 20, 2026
5-day average short volume53.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for CBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-15.

1 recent capital raiseATM program1 shelf registration

Offering Priced at $14.50/Share · Net Proceeds of ~$115.9 Million

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$13
52-week range · as of 2026-11-12 $8.72 – $27.41
Market cap
$505.64M
Volume
422.4K (1.7× avg)
3-mo avg 246K
Live data · 2026-11-21 09:08 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CBIO - Latest Insights

CBIO
Nov 12, 2026, 4:15 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.37
Real-time Price: $13.00 info
Change: -$1.37 (-10%) info
Market Cap: $505.641M info
CBIO
Nov 12, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.37
Real-time Price: $13.00 info
Change: -$1.37 (-10%) info
Market Cap: $505.641M info
CBIO
Oct 15, 2026, 4:26 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.47
Real-time Price: $13.00 info
Change: +$0.530 (+4%) info
Market Cap: $505.641M info
CBIO
Oct 05, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.91
Real-time Price: $13.00 info
Change: -$1.91 (-13%) info
Market Cap: $505.641M info
CBIO
Jul 30, 2026, 9:25 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.77
Real-time Price: $13.00 info
Change: -$1.77 (-12%) info
Market Cap: $505.641M info
CBIO
Jul 30, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.77
Real-time Price: $13.00 info
Change: -$1.77 (-12%) info
Market Cap: $505.641M info
CBIO
Jul 30, 2026, 7:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.77
Real-time Price: $13.00 info
Change: -$1.77 (-12%) info
Market Cap: $505.641M info
CBIO
Jul 20, 2026, 5:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $15.05
Real-time Price: $13.00 info
Change: -$2.05 (-14%) info
Market Cap: $505.641M info
CBIO
Jul 16, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $15.11
Real-time Price: $13.00 info
Change: -$2.11 (-14%) info
Market Cap: $505.641M info
CBIO
Jul 15, 2026, 4:56 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $15.44
Real-time Price: $13.00 info
Change: -$2.44 (-16%) info
Market Cap: $505.641M info
CBIO
Jul 14, 2026, 9:45 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $15.31
Real-time Price: $13.00 info
Change: -$2.30 (-15%) info
Market Cap: $505.641M info
CBIO
Jul 14, 2026, 4:01 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $14.00
Real-time Price: $13.00 info
Change: -$1.00 (-7%) info
Market Cap: $505.641M info
CBIO
Jul 14, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $13.00 info
Change: -$1.55 (-11%) info
Market Cap: $505.641M info
CBIO
Jul 01, 2026, 4:16 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $17.08
Real-time Price: $13.00 info
Change: -$4.08 (-24%) info
Market Cap: $505.641M info
CBIO
Apr 29, 2026, 4:28 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $20.94
Real-time Price: $13.00 info
Change: -$7.94 (-38%) info
Market Cap: $505.641M info
CBIO
Apr 29, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.94
Real-time Price: $13.00 info
Change: -$7.94 (-38%) info
Market Cap: $505.641M info
CBIO
Apr 29, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $20.94
Real-time Price: $13.00 info
Change: -$7.94 (-38%) info
Market Cap: $505.641M info
CBIO
Apr 21, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $24.61
Real-time Price: $13.00 info
Change: -$11.61 (-47%) info
Market Cap: $505.641M info
CBIO
Mar 17, 2026, 4:00 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $11.10
Real-time Price: $13.00 info
Change: +$1.90 (+17%) info
Market Cap: $505.641M info
CBIO
Feb 26, 2026, 7:27 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $12.49
Real-time Price: $13.00 info
Change: +$0.510 (+4%) info
Market Cap: $505.641M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets